Neovasc Sees Opportunities In Refractory Angina And Mitral Regurgitation Markets
Executive Summary
Neovasc Inc. is targeting two highly underserved markets in cardiology – refractory angina and mitral valve disease – with unique transcatheter solutions. The angina device, called the Neovasc Reducer, is expected to enter the European market early next year.
You may also be interested in...
Neovasc’s Reducer Shows Promise For Refractory Angina
In a small but sham-controlled trial Neovasc’s balloon-expandable implant significantly improved symptoms and quality of life in patients with refractory angina who are not candidates for other revascularization procedures. Reducer works by increasing pressure in the coronary sinus.
Early Experience With Neovasc’s Mitral Valve Is Encouraging; Edwards’ Disappoints
Physicians attending the EuroPCR conference in Paris heard presentations of first-in-man case studies on two new transcatheter mitral valve replacement technologies, one from Neovasc, and one from Edwards Lifesciences.
Transcatheter Mitral Valve Replacement Attracts Interest From Edwards, Others
Leading the development of transcatheter mitral valve replacement therapies is one of Edwards Lifesciences’ strategic imperatives, the company explained during its recent investor conference. The potential market is large, but so are the technical hurdles. Medtronic and other smaller players are also taking steps.